Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML.

(2017) A. W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)

(2012) Diane Seimetz   Journal of Cancer

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Bispecific antibodies engage T cells for antitumor immunotherapy

(2011) Bryan D Choi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

(2011) Marion G. Ott et al.   INTERNATIONAL JOURNAL OF CANCER

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

(2011) Jianying Dong et al.   mAbs

Buy buy bispecific antibodies

(2011) David Holmes   NATURE REVIEWS DRUG DISCOVERY

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

(2010) Christoph Stein et al.   BRITISH JOURNAL OF HAEMATOLOGY

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†

(2010) Jonathan H. Davis et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Antibody Internalization after Cell Surface Antigen Binding is Critical for Immunotoxin Development

(2009) Shu-Ru Kuo et al.   BIOCONJUGATE CHEMISTRY

The allogeneic graft-versus-cancer effect

(2009) Olle Ringdén et al.   BRITISH JOURNAL OF HAEMATOLOGY

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Stem cell transplants for patients with relapsed/refractory leukaemia

(2009) Hans-Jochem Kolb et al.   CURRENT OPINION IN HEMATOLOGY

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

(2009) Dirk Nagorsen et al.   LEUKEMIA & LYMPHOMA

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

(2009) Daniel A. Vallera et al.   LEUKEMIA RESEARCH

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

(2008) Denise M. Oliansky et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA

Cancer Stem Cell–Directed Therapies: Recent Data From the Laboratory and Clinic

(2008) Christopher Y Park et al.   MOLECULAR THERAPY

GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials

(2007) Jung Hee Woo et al.   PROTEIN EXPRESSION AND PURIFICATION